Year 2021 / Volume 113 / Number 1
Original
Prevalence and detection of undiagnosed active hepatitis C virus infections in Navarre, Spain, 2017-2019

28-34

DOI: 10.17235/reed.2020.7000/2020

Cristina Burgui, Carmen Martín, Aitziber Aguinaga, Alejandra Pérez-García, Carmen Ezpeleta, Jesús Castilla,

Abstract
Background: undiagnosed active hepatitis C virus (HCV) infection remains an obstacle towards its eradication. This study aimed to estimate the prevalence of HCV infection and to describe the diagnostic advances in Navarre, Spain. Methods: HCV-infection diagnostic performance was analyzed in Navarre’s primary and specialized health care between 2017 and 2019. The prevalence of undiagnosed infections was estimated for patients with programmed surgeries unrelated to HCV infection, who underwent a routine HCV antibody (anti-HCV) determination. HCV-RNA (viral load) was quantified in anti-HCV positive cases. The prevalence was standardized according to the sex and age distribution in the general population. Results: from the 63,405 subjects examined for anti-HCV, 84 (five per 100,000 person-years) were diagnosed with an active infection. In Primary Health Care, 20,363 patients were analyzed and 47 active infections were detected, i.e. one case for every 433 people tested, implying 56 % of all identified active infections. On the other hand, 9,399 surgical patients were analyzed and 120 anti-HCV positive cases were detected (adjusted prevalence: 1.47 %; 95 % CI: 1.24-1.52). A positive viral load had been determined at any time in 66 cases (0.61 %), of which five were undiagnosed active infections (adjusted prevalence: 0.04 %; 95 % CI: 0.01-0.11). Preoperative screening allowed the detection of one undiagnosed infection per 795 people analyzed aged between 45 and 64 years. Conclusions: Primary Health Care efficiently contributes to the detection of undiagnosed HCV active infections. This may be speeded up by performing population screening, targeting subjects between 45 and 64 years of age.
Share Button
New comment
Comments
No comments for this article
References
1. Bruguera M, Forns X. Hepatitis C en España. Med Clin (Barc). 2006;127:113-7. DOI: 10.1157/13090276
2. Bruggmann P, Berg T, Øvrehus AL, Moreno C, Brandão Mello CE, Roudot-Thoraval F, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat. 2014;21 Suppl 1:5-33. DOI: 10.1111/jvh.12247
3. WHO. Guidelines for the screening, care and treatment of persons with hepatitis C infection. April 2014. Disponible en: http://www.who.int/hiv/topics/hepatitis/en/
4. Ministerio de Sanidad, Servicios Sociales e Igualdad. Plan estratégico para el abordaje de la hepatitis C en el Sistema Nacional de Salud. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad, 21 de mayo de 2015. https://www.mscbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/docs/plan_estrategico_hepatitis_C.pdf
5. Buti M, Calleja JL, García-Samaniego J, et al. Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System. Med Clin (Barc) 2017;148:277-82. DOI: 10.1016/j.medcli.2016.12.018
6. Goñi-Esarte S, Juanbeltz R, Martínez-Baz I, et al. Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents. Rev Esp Enferm Dig 2019;111:445-52. DOI: 10.17235/reed.2019.6063/2018
7. Mar J, Ibarrondo O, Martinez-Baz I, et al. Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals. Rev Esp Enferm Dig 2018;110:621-8. DOI: 10.17235/reed.2018.5605/2018
8. Turnes J, Domínguez-Hernández R, Casado MA. Value and innovation of direct-acting antivirals: long-term health outcomes of the strategic plan for the management of hepatitis C in Spain. Rev Esp Enferm Dig 2017;109:809-17. DOI: 10.17235/reed.2017.5063/2017
9. Alavi M, Law MG, Valerio H, et al. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. J Hepatol 2019;71:281-8. DOI: 10.1016/j.jhep.2019.04.014
10. Crespo G, Trota N, Londoño MC, et al. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. J Hepatol 2018;69:11-7. DOI: 10.1016/j.jhep.2018.02.012
11. Kanwal F, Kramer J, Asch SM, et al. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology 2017;153:996-1005. DOI: 10.1053/j.gastro.2017.06.012
12. Kanwal F, Kramer JR, Asch SM, et al. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology; 2019. DOI: 10.1002/hep.30823
13. Cacoub P, Desbois AC, Comarmond C, et al. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut 2018;67:2025-34. DOI: 10.1136/gutjnl-2018-316234
14. Butt AA, Yan P, Shuaib A, et al. Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events. Gastroenterology 2019;156:987-96. DOI: 10.1053/j.gastro.2018.11.022
15. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. 2016. https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=
16. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93. DOI: 10.1056/NEJMoa1316366
17. Asselah T, Boyer N, Saadoun D, at al. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspective. Liver Int 2016; 36 Suppl 1: 47-57. DOI: 10.1111/liv.13027
18. Chung RT, Baumert TF. Curing chronic Hepatitis C-The arc of a medical triumph. N Engl J Med 2014; 370: 1576-78. DOI: 10.1056/NEJMp1400986
19. Juanbeltz R, Zozaya JM, Repáraz J, et al. Effectiveness of second-generation direct-acting antivirals in chronic hepatitis C. An Sist Sanit Navar 2017; 40(1): 57-66. DOI: 10.23938/ASSN.0006.
20. World Health Organization Regional Office for Europe. Action Plan for the Health Sector Response to Viral Hepatitis in the WHO European Region; WHO/Europe: Copenhagen, Denmark; 2016. [Acceso 10 de febrero de 2020]. Disponible en: http://www.euro.who.int/__data/assets/pdf_file/0017/318320/European-action-plan-HS-viral-hepatitis.pdf?ua=1
21. World Health Organization. Combating hepatitis B and C to reach elimination by 2030. Advocacy brief. WHO: Geneva, Switzerland; May 2016. [Acceso 10 de febrero de 2020]. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/206453/WHO_HIV_2016.04_eng.pdf
22. Cooke GS, Andrieux-Meyer I, Applegate TL, et al. Accelerating the elimination of viral hepatitis: A Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol 2019;4:135-84. DOI: 10.1016/S2468-1253(19)30099-8
23. Lazarus JV, Picchio C, Dillon JF, et al. Too many people with viral hepatitis are diagnosed late-with dire consequences. Nat Rev Gastroenterol Hepatol 2019;16:451-2. DOI: 10.1038/s41575-019-0177-z
24. Cabezas J, García F, Calleja Panero JL, Buti M, Molero García JM, Blasco AJ, de Mercado PL, Crespo J. Fundamentos para aplicar una estrategia de cribado poblacional de la hepatitis C en España Rev. Esp Enferm Dig 2020;112(1):64-70. DOI: 10.17235/reed.2019.6768/2019
25. Aguinaga A, Díaz-González J, Pérez-García A, et al. The prevalence of diagnosed and undiagnosed hepatitis C virus infection in Navarra, Spain, 2014-2016. Enferm Infecc Microbiol Clin 2018;36:325-31. DOI: 10.1016/j.eimc.2016.12.008
26. Grupo de trabajo del estudio de prevalencia de la infección por hepatitis C en población general en España; 2017-2018. Resultados del 2º Estudio de Seroprevalencia en España (2017-2018). Ministerio de Sanidad, Consumo y Bienestar Social; 2019. [Acceso 10 de febrero de 2020]. Disponible en: https://www.mscbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/docs/INFORME_INFECCION_VHC_ESPANA2019.pdf
27. Servicio Cántabro de Salud. Estrategia para la eliminación de la hepatitis C en Cantabria. [Acceso 10 de febrero de 2020]. Disponible en: http://www.scsalud.es/documents/ 2162705/2529917/Hepatitis+C.pdf
28. Consejería de Sanidad. Dirección General de Coordinación de Atención al Ciudadano y Humanización de la Asistencia Sanitaria. Libro Blanco de la Hepatitis C en la Comunidad de Madrid 2016-2019. Edición: Julio 2017. [Acceso 10 de febrero de 2020]. Disponible en: http://www.comunidad.madrid/publicacion/1354663261085
29. Crespo J, Albillos A, Buti M, et al. Eliminación de la hepatitis C. Documento de posicionamiento de la Asociación Española para el Estudio del Hígado (AEEH). Gastroenterol Hepatol 2019;42:579-92. DOI: 10.1016/j.gastrohep.2019.09.002
30. Instituto de Salud Pública y Laboral de Navarra. Infección por el virus de la hepatitis C en Navarra, 2015-2017. Boletín de Salud Pública de Navarra. Nº 93, agosto 2017. [Acceso 10 de febrero de 2020]. Disponible en: https://www.navarra.es/NR/rdonlyres/AECCD760-AB2A-4841-818A-FA53478FD6DC/389007/BOL9317.pdf
31. Instituto de Salud Pública y Laboral de Navarra. Infección por el virus de la hepatitis C en Navarra en 2018. Boletín de Salud Pública de Navarra. Nº 98, julio 2018. [Acceso 10 de febrero de 2020]. Disponible en: https://www.navarra.es/NR/rdonlyres/AECCD760-AB2A-4841-818A-FA53478FD6DC/423541/BOL9818.pdf
32. Instituto de Salud Pública y Laboral de Navarra. Programa de eliminación de la hepatitis C en Navarra: el necesario papel de la Atención Primaria. Boletín de Salud Pública de Navarra. Nº 104, julio 2019, pp. 5-8. [Acceso 10 de febrero de 2020]. Disponible en: https://www.navarra.es/NR/rdonlyres/AECCD760-AB2A-4841-818A-FA53478FD6DC/453684/BOL10419_2.pdf
33. Ministerio de Sanidad y Política Social. Documento marco sobre cribado poblacional; diciembre de 2010. [Acceso 10 de febrero de 2020]. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/docs/Cribado_poblacional.pdf
34. Fleiss JL. Statistical methods for rates and proportions. Toronto: John Wiley & Sons; 1973. [Acceso 10 de febrero de 2020]. Disponible en: https://onlinelibrary.wiley.com/doi/10.1002/bimj.19740160814
Related articles

Original

Hepatitis C in homeless people: reaching a hard-to-reach population

DOI: 10.17235/reed.2021.7737/2020

Citation tools
Burgui C, Martín C, Aguinaga A, Pérez-García A, Ezpeleta C, Castilla J, et all. Prevalence and detection of undiagnosed active hepatitis C virus infections in Navarre, Spain, 2017-2019. 7000/2020


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 365 visits.
This article has been downloaded 167 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 21/02/2020

Accepted: 29/04/2020

Online First: 19/11/2020

Published: 11/01/2021

Article revision time: 63 days

Article Online First time: 272 days

Article editing time: 325 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology